{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:19:07Z","timestamp":1792603147425,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005294","name":"Massachusetts General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005294","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI124718"],"award-info":[{"award-number":["R01 AI124718"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.vhri.2022.12.006","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T17:48:52Z","timestamp":1677606532000},"page":"42-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Seemingly Unrelated Regression Analysis of the Cost and Health-Related Quality of Life Outcomes of the REVAMP Randomized Clinical Trial"],"prefix":"10.1016","volume":"35","author":[{"given":"Tamlyn A.","family":"Rautenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu Kay","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahomed-Yunus S.","family":"Moosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne M.","family":"McCluskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca F.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selvan","family":"Pillay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Aturinda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Ard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winnie","family":"Muyindike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Musinguzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Godfrey","family":"Masette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melendhran","family":"Pillay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravi","family":"Moodley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaysingh","family":"Brijkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh T.","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Sunpath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mwebesa B.","family":"Bwana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent C.","family":"Marconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Siedner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vhri.2022.12.006_bib1","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/QAI.0b013e3182557785","article-title":"Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa","volume":"60","author":"Fox","year":"2012","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"4","key":"10.1016\/j.vhri.2022.12.006_bib2","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/QAD.0b013e328333bfb7","article-title":"Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa","volume":"24","author":"Boulle","year":"2010","journal-title":"AIDS"},{"issue":"7","key":"10.1016\/j.vhri.2022.12.006_bib3","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/hiv.13231","article-title":"Comparing effectiveness of first-line antiretroviral therapy between peri-urban and rural clinics in KwaZulu-Natal, South Africa","volume":"23","author":"Brijkumar","year":"2022","journal-title":"HIV Med"},{"issue":"5","key":"10.1016\/j.vhri.2022.12.006_bib4","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/jac\/dkz561","article-title":"Prevalence of viral load suppression, predictors of virological failure and patterns of HIV drug resistance after 12 and 48 months on first-line antiretroviral therapy: a national cross-sectional survey in Uganda","volume":"75","author":"Ssemwanga","year":"2020","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.vhri.2022.12.006_bib5","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1186\/s12879-017-2428-3","article-title":"Factors associated with virological non-suppression among HIV-positive patients on antiretroviral therapy in Uganda, August 2014-July 2015","volume":"17","author":"Bulage","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"6","key":"10.1016\/j.vhri.2022.12.006_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126810","article-title":"Factors that affect quality of life among people living with HIV attending an urban clinic in Uganda: a cohort study","volume":"10","author":"Mutabazi-Mwesigire","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.vhri.2022.12.006_bib7","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.idc.2019.05.004","article-title":"Management of virologic failure and HIV drug resistance","volume":"33","author":"McCluskey","year":"2019","journal-title":"Infect Dis Clin North Am"},{"issue":"1","key":"10.1016\/j.vhri.2022.12.006_bib8","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s13643-020-01524-1","article-title":"Factors associated with antiretroviral treatment failure among people living with HIV on antiretroviral therapy in resource-poor settings: a systematic review and metaanalysis","volume":"9","author":"Lailulo","year":"2020","journal-title":"Syst Rev"},{"issue":"7","key":"10.1016\/j.vhri.2022.12.006_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-036223","article-title":"Determinants of virological failure among adults on first-line highly active antiretroviral therapy at public health facilities in Kombolcha town, Northeast, Ethiopia: a case-control study","volume":"10","author":"Meshesha","year":"2020","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.vhri.2022.12.006_bib15","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1310\/4R1B-8F60-B57H-0ECN","article-title":"Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. January 28, 2000","volume":"1","year":"2000","journal-title":"HIV Clin Trials"},{"issue":"6","key":"10.1016\/j.vhri.2022.12.006_bib17","doi-asserted-by":"crossref","first-page":"440","DOI":"10.7326\/0003-4819-134-6-200103200-00008","article-title":"Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness","volume":"134","author":"Weinstein","year":"2001","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.vhri.2022.12.006_bib18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/135965350400900106","article-title":"Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV","volume":"9","author":"Corzillius","year":"2004","journal-title":"Antivir Ther"},{"issue":"6","key":"10.1016\/j.vhri.2022.12.006_bib19","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1007\/s10461-010-9799-4","article-title":"Real-time adherence monitoring for HIV antiretroviral therapy","volume":"14","author":"Haberer","year":"2010","journal-title":"AIDS Behav"},{"issue":"3","key":"10.1016\/j.vhri.2022.12.006_bib20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1473-3099(09)70328-7","article-title":"Virological follow-up of adult patients in antiretroviral treatment programmes in Sub-Saharan Africa: a systematic review","volume":"10","author":"Barth","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.vhri.2022.12.006_bib21","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1093\/cid\/civ656","article-title":"Pretreatment HIV drug resistance increases regimen switches in Sub-Saharan Africa","volume":"61","author":"Boender ST Hoenderboom","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vhri.2022.12.006_bib23","doi-asserted-by":"crossref","first-page":"d6792","DOI":"10.1136\/bmj.d6792","article-title":"Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial","volume":"343","author":"Mermin","year":"2011","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.vhri.2022.12.006_bib24","first-page":"221","article-title":"Comparative analyses of published cost effectiveness models highlight critical considerations which are useful to inform development of new models","volume":"23","author":"Rautenberg","year":"2020","journal-title":"J\u00a0Med Econ"},{"issue":"12","key":"10.1016\/j.vhri.2022.12.006_bib25","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.7326\/M21-2229","article-title":"Resistance testing for management of HIV virologic failure in Sub-Saharan Africa: an unblinded randomized controlled trial","volume":"174","author":"Siedner","year":"2021","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.vhri.2022.12.006_bib26","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/hec.584","article-title":"The death of cost-minimization analysis?","volume":"10","author":"Briggs","year":"2001","journal-title":"Health Econ"},{"issue":"11","key":"10.1016\/j.vhri.2022.12.006_bib27","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1161\/01.CIR.101.11.1297","article-title":"Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone","volume":"101","author":"Connolly","year":"2000","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.vhri.2022.12.006_bib28","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jval.2015.02.001","article-title":"Cost-effectiveness analysis alongside clinical trials II-an ISPOR Good Research Practices Task Force report","volume":"18","author":"Ramsey","year":"2015","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.vhri.2022.12.006_bib29","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jval.2019.12.009","article-title":"Cost-effectiveness of radiofrequency denervation for patients with chronic low back pain: the MINT randomized clinical trials","volume":"23","author":"Maas","year":"2020","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.vhri.2022.12.006_bib30","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.jval.2020.03.018","article-title":"Cost-utility analysis of direct-acting antivirals for treatment of chronic hepatitis C genotype 1 and 6 in Vietnam","volume":"23","author":"Due","year":"2020","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.vhri.2022.12.006_bib31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2020.11.002","article-title":"Cost-effectiveness of quadrivalent versus trivalent influenza vaccination in the Dutch national influenza prevention program","volume":"24","author":"Zeevat","year":"2021","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.vhri.2022.12.006_bib32","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/sim.7956","article-title":"Combining multiple imputation and bootstrap in the analysis of cost-effectiveness trial data","volume":"38","author":"Brand","year":"2019","journal-title":"Stat Med"},{"issue":"4","key":"10.1016\/j.vhri.2022.12.006_bib33","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/15284336.2017.1349028","article-title":"The REVAMP trial to evaluate HIV resistance testing in Sub-Saharan Africa: a case study in clinical trial design in resource limited settings to optimize effectiveness and cost effectiveness estimates","volume":"18","author":"Siedner","year":"2017","journal-title":"HIV Clin Trials"},{"issue":"5","key":"10.1016\/j.vhri.2022.12.006_bib34","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/hiv.13203","article-title":"Who\u2019s slipping through the cracks? A comprehensive individual, clinical and health system characterization of people with virological failure on first-line HIV treatment in Uganda and South Africa","volume":"23","author":"Reynolds","year":"2021","journal-title":"HIV Med"},{"issue":"1","key":"10.1016\/j.vhri.2022.12.006_bib35","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.4102\/sajhivmed.v21i1.1115","article-title":"Southern African HIV Clinicians Society guidelines for antiretroviral therapy in adults: 2020 update","volume":"21","author":"Nel","year":"2020","journal-title":"South Afr J HIV Med"},{"issue":"1","key":"10.1016\/j.vhri.2022.12.006_bib36","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1478-7954-1-11","article-title":"How do Zimbabweans value health states?","volume":"1","author":"Jelsma","year":"2003","journal-title":"Popul Health Metr"},{"key":"10.1016\/j.vhri.2022.12.006_bib37","first-page":"1","article-title":"Effects of non-orthogonality on the efficiency of seemingly unrelated regression (SUR) models","author":"Yahya WA","year":"2008","journal-title":"InterStat J"},{"issue":"1","key":"10.1016\/j.vhri.2022.12.006_bib38","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2307\/2297111","article-title":"The Lagrange multiplier test and its applications to model specification in econometrics","volume":"47","author":"Breusch","year":"1980","journal-title":"Rev Econ Stud"},{"issue":"2","key":"10.1016\/j.vhri.2022.12.006_bib39","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1586\/14737167.2014.894462","article-title":"The minimum clinically important difference for EQ-5D index: a critical review","volume":"14","author":"Coretti","year":"2014","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.vhri.2022.12.006_bib40","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12955-016-0491-x","article-title":"Comparing the performance of the EQ-5D-3L and the EQ-5D-5L in young Portuguese adults","volume":"14","author":"Ferreira","year":"2016","journal-title":"Health Qual Life Outcomes"},{"issue":"14","key":"10.1016\/j.vhri.2022.12.006_bib41","doi-asserted-by":"crossref","first-page":"291","DOI":"10.46234\/ccdcw2021.068","article-title":"Relationship between drug resistance and death in HIV-infected patients receiving antiretroviral therapy - 7 PLADs, China, 2010-2019","volume":"3","author":"Zhang","year":"2021","journal-title":"China CDC Wkly"},{"issue":"2","key":"10.1016\/j.vhri.2022.12.006_bib42","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/QAI.0000000000002850","article-title":"HIV-1 treatment failure, drug resistance, and clinical outcomes in perinatally infected children and adolescents failing first-line antiretroviral therapy in Western Kenya","volume":"89","author":"Nyandiko","year":"2022","journal-title":"J\u00a0Acquir Immune Defic Syndr"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109923000067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109923000067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:13:39Z","timestamp":1761941619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109923000067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":35,"alternative-id":["S2212109923000067"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2022.12.006","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Seemingly Unrelated Regression Analysis of the Cost and Health-Related Quality of Life Outcomes of the REVAMP Randomized Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2022.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}